Simplified theta-Defensins: Search for New Antivirals

    Authors

    P. Ruchala; S. Cho; A. L. Cole; C. Carpenter; C. L. Jung; H. Luong; E. D. Micewicz; A. J. Waring; A. M. Cole; B. C. Herold;R. I. Lehrer

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Int. J. Pept. Res. Ther.

    Keywords

    Peptides; Defensins; Antivirals; HIV-1; HSV-2; TRANSFORM INFRARED-SPECTROSCOPY; N-TERMINAL PEPTIDE; ALPHA-DEFENSINS; HIV-1 GP41; SECONDARY STRUCTURE; VIRUS TYPE-1; AMINO-ACIDS; PROTEIN; RETROCYCLIN; INFECTION; Biochemistry & Molecular Biology

    Abstract

    Peptides of the innate immune system provide intriguing templates for designing novel antiviral molecules. theta-defensins are nonhuman primate peptides with broad-spectrum antiviral activities. The activity of these compounds is mediated through interference with viral fusion, and this activity is based upon key structural features. However, two major limitations to their clinical use hampered their development as potential antivirals, namely difficult multi-step synthesis for their production with low final yield of desired product (similar to 5%), and unfavorable pharmacokinetics (rapid enzymatic degradation and/or renal clearance). Recently we designed and screened two sub-libraries of new peptide-based entry inhibitors mimicking the structure of humanized theta-defensins, designated as Hapivirins (HpVs) and Diprovirins (DpVs). Although the new peptides are smaller (13-residues) and structurally more simple than retrocyclins, several retained their ability to protect cells from infection by HIV-1 and HSV-2. The most active compound, DpV16, was chosen for a second round of modifications based on (1) its potent antiviral activity (2) its ease of synthesis, and (3) the low cost of production. Subsequently, we created a library of a second generation DpV-analogues with enhanced properties. Collectively, our findings to date suggest that simplified theta-defensins are suitable candidates for further modifications to obtain analogues with clinically favorable pharmacokinetics that may be produced in large quantities using a standard chemical approach. Considering their small size, they could be used either topically (topical microbicides) and/or for systemic applications (entry inhibitors).

    Journal Title

    International Journal of Peptide Research and Therapeutics

    Volume

    17

    Issue/Number

    4

    Publication Date

    1-1-2011

    Document Type

    Article

    Language

    English

    First Page

    325

    Last Page

    336

    WOS Identifier

    WOS:000300366900007

    ISSN

    1573-3149

    Share

    COinS